US 12,465,601 B2
Uses of phosphodiesterase inhibitors
Zejuan Sheng, Jiangsu (CN); and Frank Wu, Jiangsu (CN)
Assigned to TRANSTHERA SCIENCES (NANJING), INC., Jiangsu (CN)
Appl. No. 17/436,879
Filed by TRANSTHERA SCIENCES (NANJING), INC., Jiangsu (CN)
PCT Filed Mar. 6, 2020, PCT No. PCT/CN2020/078215
§ 371(c)(1), (2) Date Sep. 7, 2021,
PCT Pub. No. WO2020/182076, PCT Pub. Date Sep. 17, 2020.
Claims priority of application No. 201910174522.6 (CN), filed on Mar. 8, 2019; and application No. 201910235722.8 (CN), filed on Mar. 27, 2019.
Prior Publication US 2022/0160696 A1, May 26, 2022
Int. Cl. A61K 31/4545 (2006.01); A61P 9/04 (2006.01)
CPC A61K 31/4545 (2013.01) [A61P 9/04 (2018.01)] 10 Claims
 
1. A method for treating heart failure diseases in mammals, comprising administering a phosphodiesterase 9 (PDE9) inhibitor compound represented by general formula (I) or pharmaceutically acceptable salts, isomers, and deuterated compounds thereof,

OG Complex Work Unit Chemistry
wherein X1 and X4 are each CH, X2 is N, and X3 is CR3;
R3 at each occurrence is independently selected from hydrogen, deuterium, hydroxyl, amino, carboxyl, cyano, nitro, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylcarbonyl, wherein the C1-6 alkyl is not substituted or optionally substituted with one or more hydroxyl;
L is a bond;
ring A is 3-12 membered heterocyclyl wherein the heteroatom of the 3-12 membered heterocyclyl is selected from one of O, S, and N or any combination thereof;
each R1 is independently selected from hydrogen, deuterium, C1-6 alkyl, C1-6 alkoxy;
m is0, 1, 2 or 3; and
R2 is hydrogen.